Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
出版年份 2013 全文链接
标题
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
作者
关键词
Refractory gastric cancer, Chemotherapy, Capecitabine, Everolimus
出版物
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 6, Pages 1580-1586
出版商
Springer Nature
发表日期
2013-09-06
DOI
10.1007/s10637-013-0022-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
- (2012) D H Yoon et al. BRITISH JOURNAL OF CANCER
- Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
- (2012) Seong Joon Park et al. ONCOLOGY
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009
- (2012) Kyu-Won Jung et al. Cancer Research and Treatment
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
- (2011) Taekyu Lim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trends of stomach cancer mortality in Eastern Asia in 1950-2004: comparative study of Japan, Hong Kong and Singapore using age, period and cohort analysis
- (2011) Masahiro Tanaka et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
- (2011) Maarten J. Deenen et al. INVESTIGATIONAL NEW DRUGS
- Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
- (2010) Xinxin Bu et al. CANCER BIOLOGY & THERAPY
- Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo
- (2010) Daniel Cejka et al. CANCER BIOLOGY & THERAPY
- mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo
- (2010) Thorsten Fuereder et al. CANCER LETTERS
- RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
- (2010) Kyung-Hun Lee et al. CANCER LETTERS
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
- (2009) Sang Hoon Ji et al. BMC CANCER
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
- (2009) I. Okamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- The role of mTOR in the management of solid tumors: An overview
- (2008) Alex S. Strimpakos et al. CANCER TREATMENT REVIEWS
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
- (2008) Bing-Hua Jiang et al. DRUG RESISTANCE UPDATES
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started